{
    "nctId": "NCT01740271",
    "briefTitle": "A Study of Genetic Based Chemotherapy Dosing for Breast Cancer Patients",
    "officialTitle": "Pharmacogenetic Dosing of Epirubicin in FEC Chemotherapy",
    "overallStatus": "RECRUITING",
    "conditions": "Breast Neoplasms",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 48,
    "primaryOutcomeMeasure": "The goal of this study is to determine the safety of pharmacogenetic guided dosing of epirubicin for each UGT2B7 genotype.",
    "eligibilityCriteria": "Inclusion Criteria:\n\n1. Female patients with histologically confirmed non-metastatic invasive breast cancer who are scheduled to receive at least three cycles of FEC100 in the adjuvant or neoadjuvant setting\n2. Documented pathological evaluation of the breast cancer for hormone receptor (estrogen receptor \\[ER\\], progesterone receptor \\[PR\\] and HER-2 status\n3. Eastern Cooperative Oncology (ECOG) performance status of \u2264 2\n4. A Left Ventricular Ejection Fraction (LVEF) \u2265 50%.\n\nExclusion Criteria:\n\n1. Uncontrolled congestive heart failure (CHF) or angina, history of myocardial infarction within 2 months before study enrollment, or cardiac functional capacity Class III or IV as defined by the New York Heart Association Classification.\n2. Psychiatric disorder(s) that would interfere with consent, study participation, or follow up.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}